Nascent Biotech Inc NBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBIO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.09
- Day Range
- $0.10–0.10
- 52-Week Range
- $0.03–0.28
- Bid/Ask
- $0.08 / $0.10
- Market Cap
- $16.96 Mil
- Volume/Avg
- 1,700 / 60,742
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.nascentbiotech.com
Valuation
|
Metric
|
NBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 555.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NBIO
Financial Strength
|
Metric
|
NBIO
|
|---|---|
Quick Ratio | 1.02 |
Current Ratio | 1.05 |
Interest Coverage | −0.92 |
Quick Ratio
NBIO
Profitability
|
Metric
|
NBIO
|
|---|---|
Return on Assets (Normalized) | −422.76% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NBIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tlmnbcssp | Rjp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wwvgyhbd | Swfnfv | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jrjpdpxt | Dhytxm | $97.8 Bil | |
MRNA
| Moderna Inc | Qdksrsvh | Pffq | $41.3 Bil | |
ARGX
| argenx SE ADR | Jjnhpdxg | Jvjp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qhhlqjwzz | Bmnyy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pbbvmcdrp | Mztwdf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dxnnbkgg | Cmlfd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zhysfkpzf | Hqnxy | $12.5 Bil | |
INCY
| Incyte Corp | Tfskphz | Kfjlz | $11.6 Bil |